Matches in SemOpenAlex for { <https://semopenalex.org/work/W2015859997> ?p ?o ?g. }
- W2015859997 endingPage "1667" @default.
- W2015859997 startingPage "1657" @default.
- W2015859997 abstract "Imatinib is an inhibitor of the Bcr-Abl tyrosine kinase; however, resistance is common. Flavopiridol, a cyclin-dependent kinase (CDK) inhibitor, down-regulates short-lived anti-apoptotic proteins via inhibition of transcription. In preclinical studies, flavopiridol synergizes with imatinib to induce apoptosis. We investigated this novel combination regimen in patients with Bcr-Abl+ malignancies. In a phase I dose-escalation study, imatinib was administered orally daily, and flavopiridol by 1 h intravenous infusion weekly for 3 weeks every 4 weeks. Adults with chronic myelogenous leukemia or Philadelphia chromosome-positive acute leukemia were eligible. Patients were divided into two strata based on peripheral blood and bone marrow blast counts. The primary objective was to identify the recommended phase II doses for the combination. Correlative pharmacokinetic and pharmacodynamic studies were also performed. A total of 21 patients received study treatment. Four dose levels were evaluated before the study was closed following the approval of the second-generation Bcr-Abl tyrosine kinase inhibitors (TKIs). Five patients responded, including four sustained responses. Four patients had stable disease. All but one responder, and all patients with stable disease had previously been treated with imatinib. One patient had a complete response sustained for 30 months. Changes in expression of phospho-Bcr/Abl, -Stat5, and Mcl-1 were monitored. No major pharmacokinetic interaction was observed. This is the first study to evaluate the combination of a CDK inhibitor and a TKI in humans. The combination of flavopiridol and imatinib is tolerable and produces encouraging responses, including in some patients with imatinib-resistant disease." @default.
- W2015859997 created "2016-06-24" @default.
- W2015859997 creator A5001321994 @default.
- W2015859997 creator A5009840510 @default.
- W2015859997 creator A5010456775 @default.
- W2015859997 creator A5012327265 @default.
- W2015859997 creator A5013173470 @default.
- W2015859997 creator A5013926915 @default.
- W2015859997 creator A5014838335 @default.
- W2015859997 creator A5021379709 @default.
- W2015859997 creator A5030889960 @default.
- W2015859997 creator A5037312131 @default.
- W2015859997 creator A5040758762 @default.
- W2015859997 creator A5046179693 @default.
- W2015859997 creator A5052340302 @default.
- W2015859997 creator A5055228684 @default.
- W2015859997 creator A5061036144 @default.
- W2015859997 creator A5066051424 @default.
- W2015859997 creator A5069613777 @default.
- W2015859997 creator A5074069899 @default.
- W2015859997 date "2012-02-15" @default.
- W2015859997 modified "2023-10-11" @default.
- W2015859997 title "Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies" @default.
- W2015859997 cites W1777669545 @default.
- W2015859997 cites W1976244025 @default.
- W2015859997 cites W1977131009 @default.
- W2015859997 cites W1984246155 @default.
- W2015859997 cites W1989819905 @default.
- W2015859997 cites W2016656445 @default.
- W2015859997 cites W2017898416 @default.
- W2015859997 cites W2020481917 @default.
- W2015859997 cites W2028959752 @default.
- W2015859997 cites W2034074778 @default.
- W2015859997 cites W2051577500 @default.
- W2015859997 cites W2066812263 @default.
- W2015859997 cites W2068057137 @default.
- W2015859997 cites W2072874976 @default.
- W2015859997 cites W2075066807 @default.
- W2015859997 cites W2075706560 @default.
- W2015859997 cites W2081567150 @default.
- W2015859997 cites W2083967825 @default.
- W2015859997 cites W2087906534 @default.
- W2015859997 cites W2101528503 @default.
- W2015859997 cites W2105172500 @default.
- W2015859997 cites W2120328355 @default.
- W2015859997 cites W2122266760 @default.
- W2015859997 cites W2129581056 @default.
- W2015859997 cites W2132229312 @default.
- W2015859997 cites W2134582745 @default.
- W2015859997 cites W2138807703 @default.
- W2015859997 cites W2139602468 @default.
- W2015859997 cites W2141086589 @default.
- W2015859997 cites W2141972206 @default.
- W2015859997 cites W2144240156 @default.
- W2015859997 cites W2146173960 @default.
- W2015859997 cites W2158466827 @default.
- W2015859997 cites W2164452916 @default.
- W2015859997 cites W2168929418 @default.
- W2015859997 cites W2177166422 @default.
- W2015859997 cites W2571041746 @default.
- W2015859997 cites W3024398090 @default.
- W2015859997 doi "https://doi.org/10.1007/s00280-012-1839-5" @default.
- W2015859997 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3365614" @default.
- W2015859997 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22349810" @default.
- W2015859997 hasPublicationYear "2012" @default.
- W2015859997 type Work @default.
- W2015859997 sameAs 2015859997 @default.
- W2015859997 citedByCount "18" @default.
- W2015859997 countsByYear W20158599972013 @default.
- W2015859997 countsByYear W20158599972014 @default.
- W2015859997 countsByYear W20158599972015 @default.
- W2015859997 countsByYear W20158599972016 @default.
- W2015859997 countsByYear W20158599972017 @default.
- W2015859997 countsByYear W20158599972019 @default.
- W2015859997 countsByYear W20158599972020 @default.
- W2015859997 crossrefType "journal-article" @default.
- W2015859997 hasAuthorship W2015859997A5001321994 @default.
- W2015859997 hasAuthorship W2015859997A5009840510 @default.
- W2015859997 hasAuthorship W2015859997A5010456775 @default.
- W2015859997 hasAuthorship W2015859997A5012327265 @default.
- W2015859997 hasAuthorship W2015859997A5013173470 @default.
- W2015859997 hasAuthorship W2015859997A5013926915 @default.
- W2015859997 hasAuthorship W2015859997A5014838335 @default.
- W2015859997 hasAuthorship W2015859997A5021379709 @default.
- W2015859997 hasAuthorship W2015859997A5030889960 @default.
- W2015859997 hasAuthorship W2015859997A5037312131 @default.
- W2015859997 hasAuthorship W2015859997A5040758762 @default.
- W2015859997 hasAuthorship W2015859997A5046179693 @default.
- W2015859997 hasAuthorship W2015859997A5052340302 @default.
- W2015859997 hasAuthorship W2015859997A5055228684 @default.
- W2015859997 hasAuthorship W2015859997A5061036144 @default.
- W2015859997 hasAuthorship W2015859997A5066051424 @default.
- W2015859997 hasAuthorship W2015859997A5069613777 @default.
- W2015859997 hasAuthorship W2015859997A5074069899 @default.
- W2015859997 hasBestOaLocation W20158599972 @default.
- W2015859997 hasConcept C104317684 @default.
- W2015859997 hasConcept C121608353 @default.
- W2015859997 hasConcept C125418893 @default.